Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Eur J Clin Nutr ; 73(2): 319-328, 2019 02.
Article in English | MEDLINE | ID: mdl-30367156

ABSTRACT

BACKGROUND/OBJECTIVES: We aimed to describe serum 25-hydroxyvitamin D (25OHD) concentrations in older Europeans and to investigate associations between 25OHD and lifestyle factors, including dietary intake and supplement use. SUBJECTS/METHODS: Men and women aged ≥ 65 years were recruited from seven centres across north to south Europe. Serum 25OHD2 and 25OHD3 concentrations were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 4495 samples and total 25OHD (25OHD2 + 25OHD3) was adjusted for season of blood collection. RESULTS: The mean (25th, 75th quartile) of seasonally adjusted 25OHD was 46 (34, 65) nmol/L, with the highest concentration of 25OHD in Bergen [61 (49, 79) nmol/L], and the lowest in Paris [36 (24, 57) nmol/L)]. Vitamin D deficiency (25-50 nmol/L) and vitamin D insufficiency (50-75 nmol/L) were found in 41 and 33% of the population, respectively. In multivariable analysis controlled for confounders, seasonally adjusted 25OHD concentrations were significantly (p < 0.05) lower in smokers and participants with self-reported diabetes and higher with increasing dietary vitamin D, and supplement use with fish liver oil, omega-3, and vitamin D. Additionally, in further analysis excluding Bergen, 25OHD was associated with higher intakes of oily fish and increasing UVB exposure. We observed low concentrations of 25OHD in older people in Europe. CONCLUSIONS: Our findings of the higher 25OHD concentrations in supplement users (omega-3 fish oil, fish liver oil, vitamin D) add to current recommendations to reduce vitamin D deficiency. We were unable to fully assess the role of dietary vitamin D as we lacked information on vitamin D-fortified foods.


Subject(s)
Diet , Life Style , Macular Degeneration/prevention & control , Vitamin D Deficiency/epidemiology , Vitamin D/analogs & derivatives , Aged , Cross-Sectional Studies , Demography , Dietary Supplements , Europe/epidemiology , Female , Health Services for the Aged , Humans , Male , Prevalence , Socioeconomic Factors , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D Deficiency/blood
2.
Br J Nutr ; 120(1): 74-80, 2018 07.
Article in English | MEDLINE | ID: mdl-29936925

ABSTRACT

Vitamin D deficiency is a common occurrence globally, and particularly so in pregnancy. There is conflicting evidence regarding the role of vitamin D during pregnancy in non-skeletal health outcomes for both the mother and the neonate. The aim of this study was to investigate the associations of maternal total 25-hydroxy vitamin D (25OHD) with neonatal anthropometrics and markers of neonatal glycaemia in the Belfast centre of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Serological samples (n 1585) were obtained from pregnant women in the Royal Jubilee Maternity Hospital, Belfast, Northern Ireland, between 24 and 32 weeks' gestation as part of the HAPO study. 25OHD concentrations were measured by liquid chromatography tandem-MS. Cord blood and neonatal anthropometric measurements were obtained within 72 h of birth. Statistical analysis was performed. After adjustment for confounders, birth weight standard deviation scores (SDS) and birth length SDS were significantly associated with maternal total 25OHD. A doubling of maternal 25OHD at 28 weeks' gestation was associated with mean birth weight SDS and mean birth length SDS higher by 0·05 and 0·07, respectively (both, P=0·03). There were no significant associations with maternal 25OHD and other measures of neonatal anthropometrics or markers of neonatal glycaemia. In conclusion, maternal total 25OHD during pregnancy was independently associated with several neonatal anthropometric measurements; however, this association was relatively weak.


Subject(s)
Hyperglycemia/blood , Hyperglycemia/complications , Vitamin D/blood , Adult , Anthropometry , Birth Weight , Blood Glucose , Diabetes Mellitus/blood , Diabetes, Gestational/blood , Fasting , Female , Fetal Blood , Gestational Age , Glucose Tolerance Test , Homeostasis , Humans , Infant, Newborn , Insulin-Secreting Cells/metabolism , Mothers , Northern Ireland , Pregnancy , Pregnancy Complications , Pregnancy Outcome , Vitamin D Deficiency/complications
3.
Ophthalmology ; 124(1): 90-96, 2017 01.
Article in English | MEDLINE | ID: mdl-28029444

ABSTRACT

PURPOSE: To study associations between early and late age-related macular degeneration (AMD) and neovascular AMD (nvAMD) with serum 25-hydroxy vitamin D (25(OH)D) and genetic variants in vitamin D pathway genes. DESIGN: Population-based, cross-sectional study in a random sample aged 65 years or older from 7 European countries. PARTICIPANTS: Of 4753 participants, 4496 (2028 men and 2468 women), with a mean age of 73 years, provided a blood sample; 2137 had no signs of AMD, 2209 had early AMD, and 150 had late AMD, of whom 104 had nvAMD. METHODS: Participants were interviewed to determine smoking and alcohol use, sunlight exposure, and diet; underwent fundus photography. Fundus images were graded using the International Classification System for Age-Related Maculopathy. The 25(OH)D was measured by liquid chromatography-tandem mass spectrometry and categorized as deficient (<30 nmol/l), insufficient (30-50 nmol/l), or adequate (≥50 nmol/l). Genotyping was performed on a subsample of 1284 AMD cases and controls for 93 single nucleotide polymorphisms (SNPs) from 7 genes. Associations were investigated by linear or logistic regression adjusted for potential confounders. MAIN OUTCOME MEASURES: Adjusted odds ratio (OR) for 3 outcomes (early AMD, late AMD, nvAMD). RESULTS: No linear association was found with 25(OH)D and early or late AMD or nvAMD. There was no association between insufficient or deficient status with early or late AMD. Deficient status was associated with nvAMD (adjusted OR, 1.27; 95% confidence interval, 1.1-1.45; P < 0.0001). Significant (P < 0.05) associations with 25(OH)D were found for SNPs in genes GC, VDR, CYP2R1, and CYP27B1. Two SNPs (VDR) were associated with early AMD, 4 SNPs (RXRA) and 1 SNP (VDR) were associated with nvAMD, and 1 SNP (RXRA), 2 SNPs (VDR), and 1 SNP (CYP2R1) were associated with late AMD. After Bonferroni correction, no SNPs were associated with early AMD, late AMD, or nvAMD. CONCLUSIONS: Deficiency in 25(OH)D was associated with nvAMD, but the adjusted OR was small, and we cannot exclude residual confounding. The hypothesis of a causal association of vitamin D with AMD is not supported by clear evidence for an association of vitamin D SNPs with early AMD, late AMD, or nvAMD.


Subject(s)
Genetic Variation , Macular Degeneration/blood , Macular Degeneration/genetics , Vitamin D Deficiency/genetics , Vitamin D/analogs & derivatives , Aged , Aged, 80 and over , Choroidal Neovascularization/blood , Choroidal Neovascularization/genetics , Cross-Sectional Studies , Female , Genotype , Humans , Male , Odds Ratio , Polymorphism, Single Nucleotide , Vitamin D/blood , Vitamin D Deficiency/blood , White People
4.
JAMA Ophthalmol ; 135(1): 47-53, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27918775

ABSTRACT

IMPORTANCE: Myopia is becoming increasingly common globally and is associated with potentially sight-threatening complications. Spending time outdoors is protective, but the mechanism underlying this association is poorly understood. OBJECTIVE: To examine the association of myopia with ultraviolet B radiation (UVB; directly associated with time outdoors and sunlight exposure), serum vitamin D concentrations, and vitamin D pathway genetic variants, adjusting for years in education. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional, population-based random sample of participants 65 years and older was chosen from 6 study centers from the European Eye Study between November 6, 2000, to November 15, 2002. Of 4187 participants, 4166 attended an eye examination including refraction, gave a blood sample, and were interviewed by trained fieldworkers using a structured questionnaire. Myopia was defined as a mean spherical equivalent of -0.75 diopters or less. Exclusion criteria included aphakia, pseudophakia, late age-related macular degeneration, and vision impairment due to cataract, resulting in 371 participants with myopia and 2797 without. EXPOSURES: Exposure to UVB estimated by combining meteorological and questionnaire data at different ages, single-nucleotide polymorphisms in vitamin D metabolic pathway genes, serum vitamin D3 concentrations, and years of education. MAIN OUTCOMES AND MEASURES: Odds ratios (ORs) of UVB, serum vitamin D3 concentrations, vitamin D single-nucleotide polymorphisms, and myopia estimated from logistic regression. RESULT: Of the included 3168 participants, the mean (SD) age was 72.4 (5) years, and 1456 (46.0%) were male. An SD increase in UVB exposure at age 14 to 19 years (OR, 0.81; 95% CI, 0.71-0.92) and 20 to 39 years (OR, 0.7; 95% CI, 0.62-0.93) was associated with a reduced adjusted OR of myopia; those in the highest tertile of years of education had twice the OR of myopia (OR, 2.08; 95% CI, 1.41-3.06). No independent associations between myopia and serum vitamin D3 concentrations nor variants in genes associated with vitamin D metabolism were found. An unexpected finding was that the highest quintile of plasma lutein concentrations was associated with a reduced OR of myopia (OR, 0.57; 95% CI, 0.46-0.72). CONCLUSIONS AND RELEVANCE: Increased UVB exposure was associated with reduced myopia, particularly in adolescence and young adulthood. The association was not altered by adjusting for education. We found no convincing evidence for a direct role of vitamin D in myopia risk. The relationship between high plasma lutein concentrations and a lower risk of myopia requires replication.


Subject(s)
DNA/genetics , Myopia/blood , Polymorphism, Single Nucleotide , Population Surveillance , Refraction, Ocular/radiation effects , Ultraviolet Rays/adverse effects , Vitamin D/blood , Adult , Aged , Cross-Sectional Studies , Europe/epidemiology , Humans , Metabolic Networks and Pathways , Middle Aged , Myopia/epidemiology , Myopia/genetics , Odds Ratio , Retrospective Studies , Visual Acuity , Young Adult
5.
J Cardiovasc Nurs ; 32(2): 148-155, 2017.
Article in English | MEDLINE | ID: mdl-26829748

ABSTRACT

BACKGROUND: Observational studies suggest that patients with heart failure have a tendency to a reduced status of a number of micronutrients and that this may be associated with an adverse prognosis. A small number of studies also suggest that patients with heart failure may have reduced dietary intake of micronutrients, a possible mechanism for reduced status. OBJECTIVE: The aims of this study were to assess dietary micronutrient intake and micronutrient status in a group of patients with heart failure. METHODS: Dietary intake was assessed in 79 outpatients with chronic stable heart failure with a reduced ejection fraction using a validated food frequency questionnaire. Blood concentrations of a number of micronutrients, including vitamin D, were measured in fasting blood samples, drawn at the time of food frequency questionnaire completion. RESULTS: More than 20% of patients reported intakes less than the reference nutrient intake or recommended intake for riboflavin, vitamin D, vitamin A, calcium, magnesium, potassium, zinc, copper, selenium, and iodine. More than 5% of patients reported intakes less than the lower reference nutrient intake or minimum recommended intake for riboflavin, vitamin D, vitamin A, calcium, magnesium, potassium, zinc, selenium, and iodine. Vitamin D deficiency (plasma total 25-hydroxy-vitamin D concentration <50 nmol/L) was observed in 75.6% of patients. CONCLUSIONS: Vitamin D deficiency was common in this group of patients with heart failure. Based on self-reported dietary intake, a substantial number of individuals may not have been consuming enough vitamin D and a modest number of individuals may not have been consuming enough riboflavin, vitamin A, calcium, magnesium, potassium, zinc, copper, selenium, or iodine to meet their dietary needs.


Subject(s)
Energy Intake , Heart Failure/complications , Micronutrients , Nutritional Status , Vitamin D Deficiency/epidemiology , Aged , Chronic Disease , Female , Heart Failure/psychology , Humans , Male , Middle Aged , Self Report
6.
J Diabetes Complications ; 30(1): 109-14, 2016.
Article in English | MEDLINE | ID: mdl-26597598

ABSTRACT

AIM: In view of the increased rates of pre-eclampsia observed in diabetic pregnancy and the lack of ex vivo data on placental biomarkers of oxidative stress in T1 diabetic pregnancy, the aim of the current investigation was to examine placental antioxidant enzyme status and lipid peroxidation in pregnant women with type 1 diabetes. A further objective of the study was to investigate the putative impact of vitamin C and E supplementation on antioxidant enzyme activity and lipid peroxidation in type 1 diabetic placentae. METHODS: The current study measured levels of antioxidant enzyme [glutathione peroxidase (Gpx), glutathione reductase (Gred), superoxide dismutase (SOD) and catalase] activity and degree of lipid peroxidation (aqueous phase hydroperoxides and 8-iso-prostaglandin F2α) in matched central and peripheral samples from placentae of DAPIT (n=57) participants. Levels of vitamin C and E were assessed in placentae and cord blood. RESULTS: Peripheral placentae demonstrated significant increases in Gpx and Gred activities in pre-eclamptic in comparison to non-pre-eclamptic women. Vitamin C and E supplementation had no significant effect on cord blood or placental levels of these vitamins, nor on placental antioxidant enzyme activity or degree of lipid peroxidation in comparison to placebo-supplementation. CONCLUSION: The finding that maternal supplementation with vitamin C/E does not augment cord or placental levels of these vitamins is likely to explain the lack of effect of such supplementation on placental indices including antioxidant enzymes or markers of lipid peroxidation.


Subject(s)
Ascorbic Acid/therapeutic use , Diabetes Mellitus, Type 1/diet therapy , Dietary Supplements , Maternal Nutritional Physiological Phenomena , Placenta/enzymology , Pregnancy in Diabetics/diet therapy , Vitamin E/therapeutic use , Ascorbic Acid/blood , Ascorbic Acid/metabolism , Biomarkers/blood , Biomarkers/metabolism , Cohort Studies , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/metabolism , Female , Fetal Blood , Humans , Lipid Peroxidation , Northern Ireland/epidemiology , Oxidative Stress , Oxidoreductases/chemistry , Oxidoreductases/metabolism , Placenta/metabolism , Pre-Eclampsia/epidemiology , Pre-Eclampsia/prevention & control , Pregnancy , Pregnancy in Diabetics/blood , Pregnancy in Diabetics/enzymology , Pregnancy in Diabetics/metabolism , Pregnancy, High-Risk/blood , Pregnancy, High-Risk/metabolism , Risk , Vitamin E/blood , Vitamin E/metabolism
7.
JACC Heart Fail ; 2(3): 308-17, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24952700

ABSTRACT

OBJECTIVES: This study sought to investigate the effect of a multiple micronutrient supplement on left ventricular ejection fraction (LVEF) in patients with heart failure. BACKGROUND: Observational studies suggest that patients with heart failure have reduced intake and lower concentrations of a number of micronutrients. However, there have been very few intervention studies investigating the effect of micronutrient supplementation in patients with heart failure. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group study involving 74 patients with chronic stable heart failure that compared multiple micronutrient supplementation taken once daily versus placebo for 12 months. The primary endpoint was LVEF assessed by cardiovascular magnetic resonance imaging or 3-dimensional echocardiography. Secondary endpoints were Minnesota Living With Heart Failure Questionnaire score, 6-min walk test distance, blood concentrations of N-terminal prohormone of brain natriuretic peptide, C-reactive protein, tumor necrosis factor alpha, interleukin-6, interleukin-10, and urinary levels of 8-iso-prostaglandin F2 alpha. RESULTS: Blood concentrations of a number of micronutrients increased significantly in the micronutrient supplement group, indicating excellent compliance with the intervention. There was no significant difference in mean LVEF at 12 months between treatment groups after adjusting for baseline (mean difference: 1.6%, 95% confidence interval: -2.6 to 5.8, p = 0.441). There was also no significant difference in any of the secondary endpoints at 12 months between treatment groups. CONCLUSIONS: This study provides no evidence to support the routine treatment of patients with chronic stable heart failure with a multiple micronutrient supplement. (Micronutrient Supplementation in Patients With Heart Failure [MINT-HF]; NCT01005303).


Subject(s)
Heart Failure/diet therapy , Micronutrients/administration & dosage , Stroke Volume/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Chronic Disease , Dietary Supplements , Double-Blind Method , Echocardiography/methods , Exercise Test , Exercise Tolerance/physiology , Female , Heart Failure/physiopathology , Humans , Magnetic Resonance Angiography/methods , Male , Medication Adherence , Middle Aged , Treatment Outcome , Young Adult
8.
PLoS One ; 8(9): e74068, 2013.
Article in English | MEDLINE | ID: mdl-24019947

ABSTRACT

OBJECTIVE: The first aim of this study was to assess 25-hydroxy vitamin D (25OHD) concentrations in women with type 1 diabetes (T1DM) during pregnancy, post-delivery and also foetal (cord blood) 25OHD concentrations and to examine relationships between these. The second aim of the study was to investigate potential interactions between maternal body mass index (BMI) and foetal vitamin D status. A further study aim was to examine potential relationships between maternal 25OHD and glycosylated haemoglobin (HbA1c) throughout pregnancy. RESEARCH DESIGN AND METHODS: This was an observational study of 52 pregnant controls without diabetes and 65 pregnant women with T1DM in a university teaching hospital. Maternal serum 25OHD was measured serially throughout the pregnancy and post-delivery. Cord blood 25OHD was measured at delivery. 25OHD was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). RESULTS: Vitamin D deficiency (25OHD <25 nmol/L) was apparent in both the T1DM subjects and controls at all 3 pregnancy trimesters. Vitamin D levels in all cord blood were <50 nmol/L. Maternal 25OHD correlated positively with cord 25OHD at all 3 trimesters in the T1DM group (p=0.02; p<0.001; p<0.001). 25OHD levels within cord blood were significantly lower for women with diabetes classified as obese vs. normal weight at booking [normal weight BMI <25 kg/m(2) vs. obese BMI >30 kg/m(2) (nmol/L ± SD); 19.93 ± 11.15 vs. 13.73 ± 4.74, p=0.026]. In the T1DM group, HbA1c at booking was significantly negatively correlated with maternal 25OHD at all 3 trimesters (p=0.004; p=0.001; p=0.05). CONCLUSION: In T1DM pregnancy, low vitamin D levels persist throughout gestation and post-delivery. Cord blood vitamin D levels correlate with those of the mother, and are significantly lower in obese women than in their normal weight counterparts. Maternal vitamin D levels exhibit a significant negative relationship with HbA1c levels, supporting a potential role for this vitamin in maintaining glycaemic control.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 1/blood , Pregnancy in Diabetics/blood , Vitamin D/analogs & derivatives , Adult , Case-Control Studies , Diabetes Mellitus, Type 1/complications , Female , Humans , Infant, Newborn , Pregnancy , Pregnancy Outcome , Vitamin D/blood
9.
Atherosclerosis ; 226(2): 392-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23287638

ABSTRACT

INTRODUCTION: High density lipoproteins (HDL) have considerable potential for improving cardiovascular health. Additionally, epidemiological studies have identified an inverse relationship between α-tocopherol intake and cardiovascular disease, which has not been translated in randomised controlled trials. OBJECTIVES: This study assessed if increased α-tocopherol within HDL(2) and HDL(3) (HDL(2&3)) influenced their antiatherogenic potential. In the first of two in vitro investigations, the oxidation potential of HDL(2&3) was assessed when α-tocopherol was added following their isolation. In the second, their oxidation potential was assessed when HDL(2&3) were isolated from serum pre-incubated with α-tocopherol. Additionally, a 6-week placebo-controlled intervention with α-tocopherol assessed if α-tocopherol influenced the oxidation potential and activities of HDL(2&3)-associated enzymes, paraoxonase-1 (PON-1) and lecithin cholesteryl acyltransferase (LCAT). RESULTS: Conflicting results arose from the in vitro investigations, whereby increasing concentrations of α-tocopherol protected HDL(2&3) against oxidation in the post-incubated HDL(2&3), and promoted HDL(2&3)-oxidation when they were isolated from serum pre-incubated with α-tocopherol. Following the 6-week placebo-controlled investigation, α-tocopherol increased in HDL(2&3), while HDL(2&3) became more susceptible to oxidation, additionally the activities of HDL(2&3)-PON-1 and HDL(2)-LCAT decreased. CONCLUSION: These results have shown for the first time that α-tocopherol induces changes to HDL(2&3), which could contribute to the pathophysiology of cardiovascular disease.


Subject(s)
Lipoproteins, HDL2/drug effects , Lipoproteins, HDL3/drug effects , Reactive Oxygen Species/pharmacology , alpha-Tocopherol/pharmacology , Adult , Aryldialkylphosphatase/metabolism , Atherosclerosis/etiology , Female , Humans , Lipoproteins, HDL/blood , Male , Oxidation-Reduction , Phosphatidylcholine-Sterol O-Acyltransferase/metabolism
10.
J Nutr Biochem ; 24(1): 163-8, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22819555

ABSTRACT

The management of overweight subjects by interventions aimed at reducing inflammation is highly desirable. To date, observational studies have identified a link between increased dietary antioxidant intake and reduced cardiovascular morbidity. However, direct trial evidence regarding the ability of antioxidants to influence inflammation is lacking. Therefore, this study examined lycopene's ability to lower systemic and high-density lipoprotein (HDL)-associated inflammation in moderately overweight middle-aged subjects. Serum was collected before and after a 12-week intervention from 54 moderately overweight, middle-aged individuals. Subjects were randomised to one of three groups: control diet (<10 mg lycopene/week), lycopene-rich diet (224-350 mg lycopene/week) and lycopene supplement (70 mg lycopene/week). HDL was subfractionated into HDL(2&3) by rapid ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum and HDL(2&3). Systemic and HDL-associated inflammation was assessed by measuring serum amyloid A (SAA) levels. HDL functionality was determined by monitoring the activities of paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin cholesterol acyltransferase (LCAT). Lycopene increased in serum and HDL(2&3) following both lycopene interventions (P<.001, for all), while SAA decreased in serum following the lycopene supplement and in HDL(3) following both lycopene interventions (P<.05 for all). PON-1 activity increased in serum and HDL(2&3) in both lycopene groups (P<.05, for all). Furthermore, the activity of CETP decreased in serum following the lycopene supplement, while the activity of LCAT increased in serum and HDL(3) following both lycopene interventions (P<.05 for all). These results demonstrate that in moderately overweight, middle-aged subjects, increasing lycopene intake leads to changes to HDL(2&3), which we suggest enhanced their antiatherogenic properties. Overall, these results show the heart-protective properties of increased lycopene intake.


Subject(s)
Carotenoids/therapeutic use , Lipoproteins, HDL/blood , Overweight/drug therapy , Apolipoprotein A-I/blood , Aryldialkylphosphatase/blood , Carotenoids/blood , Cholesterol Ester Transfer Proteins/blood , Humans , Lycopene , Middle Aged , Overweight/blood , Phosphatidylcholine-Sterol O-Acyltransferase/blood , Serum Amyloid A Protein/analysis
11.
Ann Clin Biochem ; 50(Pt 1): 20-4, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23148280

ABSTRACT

BACKGROUND: The worldwide epidemic of obesity is a major public health concern and is persuasively linked to the rising prevalence of diabetes and cardiovascular disease. Obesity is often associated with an abnormal lipoprotein profile, which may be partly negated by pioglitazone intervention, as this can influence the composition and oxidation characteristics of low-density lipoprotein (LDL). However, as pioglitazone's impact on these parameters within high-density lipoprotein (HDL), specifically HDL(2&3), is absent from the literature, this study was performed to address this shortcoming. METHODS: Twenty men were randomized to placebo or pioglitazone (30 mg/day) for 12 weeks. HDL(2&3) were isolated by rapid-ultracentrifugation. HDL(2&3)-cholesterol and phospholipid content were assessed by enzymatic assays and apolipoprotein AI (apoAI) content by single-radial immunodiffusion. HDL(2&3) oxidation characteristics were assessed by monitoring conjugated diene production and paraoxonase-1 activity by spectrophotometric assays. RESULTS: Compared with the placebo group, pioglitazone influenced the composition and oxidation potential of HDL(2&3). Specifically, total cholesterol (P < 0.05), phospholipid (P < 0.001) and apoAI (P < 0.001) were enriched within HDL(2). Furthermore, the resistance of HDL(2&3) to oxidation (P < 0.05) and the activity of paroxonase-1 were also increased (P < 0.001). CONCLUSIONS: Overall, these findings indicate that pioglitazone treatment induced antiatherogenic changes within HDL(2&3), which may help reduce the incidence of premature cardiovascular disease linked with obesity.


Subject(s)
Apolipoprotein A-I/blood , Aryldialkylphosphatase/blood , Cholesterol, HDL/blood , Hypoglycemic Agents/pharmacology , Obesity/blood , Thiazolidinediones/pharmacology , Adult , Body Mass Index , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Fasting , Humans , Immunodiffusion , Male , Middle Aged , Obesity/complications , Oxidation-Reduction , Pioglitazone , Spectrophotometry , Ultracentrifugation
12.
Clin Endocrinol (Oxf) ; 79(6): 800-6, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23170936

ABSTRACT

OBJECTIVE: Central obesity and insulin resistance are key components of the metabolic syndrome, which is associated with an increased risk of cardiovascular disease. In obesity, CC chemokines, such as monocyte chemotactic protein-1 (MCP-1), macrophage inhibitory protein-1ß (MIP-1ß) and eotaxin-1 and their respective receptors, are critically involved in peripheral monocyte activation and adipose tissue infiltration. The aim of the current study was to examine whether low-dose atorvastatin (10 mg/d) treatment modulated serum levels of CC chemokines in metabolic syndrome subjects. MATERIALS AND METHODS: Serum levels of MCP-1, eotaxin-1, MIP-1ß, C reactive protein (CRP) and interleukin-6 (IL-6) were measured in lean control and metabolic syndrome subjects at baseline, and following a 6-week randomized placebo-controlled clinical trial of atorvastatin (10 mg/d). Peripheral CD14(+) monocytes were isolated and mRNA levels of MCP-1, MIP-1 ß and CCR5 determined. RESULTS: Serum MCP-1 (P = 0·02), eotaxin-1 (P = 0·02) and MIP-1ß (P = 0·03), CRP (P < 0·001) and IL-6 (P = 0·006) were significantly increased in metabolic syndrome in comparison with lean controls. Furthermore, CD14(+) peripheral monocyte mRNA expression of the chemokine receptor, CCR5, of which MIP-1ß and eotaxin-1 are ligands, was increased two-fold in the metabolic syndrome group (P = 0·03). In addition to the expected improvements in lipid profile, atorvastatin treatment significantly reduced circulating eotaxin-1 (P < 0·05), MIP-1ß (P < 0·05) levels and CD14(+) peripheral monocyte CCR5 mRNA expression (P = 0·02). CONCLUSION: These results support a model whereby atorvastatin treatment, by inhibiting CD14(+) monocyte CCR5 expression, may inhibit monocyte trafficking, reduce chronic inflammation and, thus, lower circulating levels of CC chemokines.


Subject(s)
Chemokines, CC/blood , Heptanoic Acids/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Metabolic Syndrome/blood , Metabolic Syndrome/drug therapy , Pyrroles/administration & dosage , Adult , Anticholesteremic Agents/administration & dosage , Atorvastatin , C-Reactive Protein/metabolism , Chemokine CCL11/blood , Chemokine CCL2/blood , Chemokine CCL2/genetics , Chemokine CCL4/blood , Chemokine CCL4/genetics , Chemokines, CC/genetics , Female , Humans , Inflammation Mediators/blood , Interleukin-6/blood , Male , Metabolic Syndrome/genetics , Middle Aged , Monocytes/metabolism , RNA, Messenger/blood , RNA, Messenger/genetics , Receptors, CCR5/blood , Receptors, CCR5/genetics
13.
Clin Sci (Lond) ; 123(3): 135-46, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22309242

ABSTRACT

Obese AT (adipose tissue) exhibits increased macrophage number. Pro-inflammatory CD16+ peripheral monocyte numbers are also reported to increase with obesity. The present study was undertaken to simultaneously investigate obesity-associated changes in CD16+ monocytes and ATMs (AT macrophages). In addition, a pilot randomized placebo controlled trial using the PPAR (peroxisome-proliferator-activated receptor) agonists, pioglitazone and fenofibrate was performed to determine their effects on CD14+/CD16+ monocytes, ATM and cardiometabolic and adipose dysfunction indices. Obese glucose-tolerant men (n=28) were randomized to placebo, pioglitazone (30 mg/day) and fenofibrate (160 mg/day) for 12 weeks. A blood sample was taken to assess levels of serum inflammatory markers and circulating CD14+/CD16+ monocyte levels via flow cytometry. A subcutaneous AT biopsy was performed to determine adipocyte cell surface and ATM number, the latter was determined via assessment of CD68 expression by IHC (immunohistochemistry) and real-time PCR. Subcutaneous AT mRNA expression of CEBPß (CCAAT enhancer-binding protein ß), SREBP1c (sterol-regulatory-element-binding protein 1c), PPARγ2, IRS-1 (insulin receptor substrate-1), GLUT4 (glucose transporter type 4) and TNFα (tumour necrosis factor α) were also assessed. Comparisons were made between obese and lean controls (n=16) at baseline, and pre- and post-PPAR agonist treatment. Obese individuals had significantly increased adipocyte cell surface, percentage CD14+/CD16+ monocyte numbers and ATM number (all P=0.0001). Additionally, serum TNF-α levels were significantly elevated (P=0.017) and adiponectin levels reduced (total: P=0.0001; high: P=0.022) with obesity. ATM number and percentage of CD14+/CD16+ monocytes correlated significantly (P=0.05). Pioglitazone improved adiponectin levels significantly (P=0.0001), and resulted in the further significant enlargement of adipocytes (P=0.05), without effect on the percentage CD14+/CD16+ or ATM number. Pioglitazone treatment also significantly increased subcutaneous AT expression of CEBPß mRNA. The finding that improvements in obesity-associated insulin resistance following pioglitazone were associated with increased adipocyte cell surface and systemic adiponectin levels, supports the centrality of AT to the cardiometabolic derangement underlying the development of T2D (Type 2 diabetes) and CVD (cardiovascular disease).


Subject(s)
Adipose Tissue/physiopathology , CCAAT-Enhancer-Binding Protein-beta/genetics , Obesity/drug therapy , Obesity/physiopathology , Recovery of Function , Thiazolidinediones/therapeutic use , Up-Regulation/genetics , Adipocytes/drug effects , Adipocytes/metabolism , Adiponectin/metabolism , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Adult , Aged , Anthropometry , Biomarkers/metabolism , CCAAT-Enhancer-Binding Protein-beta/metabolism , Cardiovascular Diseases/pathology , Cell Count , Cell Membrane/drug effects , Cell Membrane/metabolism , Cytokines/blood , Fenofibrate/pharmacology , Fenofibrate/therapeutic use , Glucose Tolerance Test , Humans , Inflammation Mediators/blood , Male , Middle Aged , Monocytes/metabolism , Obesity/blood , Pioglitazone , Recovery of Function/drug effects , Risk Factors , Thiazolidinediones/pharmacology , Up-Regulation/drug effects
14.
J Nutr Biochem ; 23(6): 685-90, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21840193

ABSTRACT

The effects of polyunsaturated n-6 linoleic acid on monocyte-endothelial interactions were investigated with particular emphasis on the expression of platelet/endothelial cell adhesion molecule (PECAM)-1 and the role of protein kinase C (PKC) and cyclooxygenase-2 (COX-2). As a diet rich in polyunsaturated fatty acids may favour atherosclerosis in hyperglycaemia, this study was performed in both normal and high-glucose media using human aortic endothelial cells (HAEC). The HAEC were preincubated with normal (5 mM) or high (25 mM) D-glucose for 3 days before addition of fatty acids (0.2 mM) for 3 days. Linoleic acid enhanced PECAM-1 expression independently of tumor necrosis factor (TNF)-α and significantly increased TNF-α-induced monocyte adhesion to HAEC in comparison to the monounsaturated n-9 oleic acid. Chronic glucose treatment (25 mM, 6 days) did not modify the TNF-α-induced or fatty acid-induced changes in monocyte binding. The increase in monocyte binding was accompanied by a significant increase in E-selectin and vascular cell adhesion molecule (VCAM)-1 expression and could be abrogated by an interleukin (IL)-8 neutralising antibody and by the PKC and COX inhibitors. Inhibition of PKC-δ reduced VCAM-1 expression regardless of experimental condition and was accompanied by a significant decrease in monocyte binding. Conditioned medium from linoleic acid-treated HAEC grown in normal glucose conditions significantly increased THP-1 chemotaxis. These results suggest that linoleic acid-induced changes in monocyte chemotaxis and subsequent binding are not solely mediated by changes in adhesion molecule expression but may be due to secreted factors such as IL-8, monocyte chemoattractant protein-1 or prostaglandins (PGs) such as PGE(2), as IL-8 neutralisation and COX-2 inhibition reduced monocyte binding without changes in adhesion molecule expression.


Subject(s)
Cell Adhesion Molecules/drug effects , Chemotaxis, Leukocyte/drug effects , Cyclooxygenase 2/genetics , Endothelial Cells/drug effects , Linoleic Acid/pharmacology , Monocytes/drug effects , Protein Kinase C/metabolism , Aorta/cytology , Aorta/drug effects , Aorta/metabolism , Blood Glucose/analysis , Cells, Cultured , Chemokine CCL2/metabolism , Cyclooxygenase 2/metabolism , E-Selectin/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Humans , Interleukin-8/metabolism , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Tumor Necrosis Factor-alpha/metabolism , Vascular Cell Adhesion Molecule-1/metabolism
15.
Biochim Biophys Acta ; 1821(2): 335-42, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22138303

ABSTRACT

Cyclooxygenase-2 (Cox-2) and Apo J/clusterin are involved in inflammatory resolution and have each been reported to inhibit NF-κB signalling. Using a well-validated rat pheochromocytoma (PC12) cell culture model of Cox-2 over-expression the current study investigated inter-dependence between Cox-2 and clusterin with respect to induction of expression and impact on NF-κB signalling. Both gene expression and immunoblot analysis confirmed that intracellular and secreted levels of clusterin were elevated in Cox-2 over-expressing cells (PCXII). Clusterin expression was increased in control (PCMT) cells in a time- and dose-dependent manner by 15-deoxy-Δ(12,14)-prostaglandin J(2) (15d-PGJ(2)), but not PGE(2), and inhibited in PCXII cells by pharmacological Cox inhibition. In PCXII cells, inhibition of two transcription factors known to be activated by 15d-PGJ(2), heat shock factor 1 (HSF-1) and peroxisome proliferator activated receptor (PPAR)γ, by transcription factor oligonucleotide decoy and antagonist (GW9662) treatment, respectively, reduced clusterin expression. While PCXII cells exhibited reduced TNF-α-induced cell surface ICAM-1 expression, IkB phosphorylation and degradation were similar to control cells. With respect to the impact of Cox-2-dependent clusterin upregulation on NF-κB signalling, basal levels of IκB were similar in control and PCXII cells, and no evidence for a physical association between clusterin and phospho-IκB was obtained. Moreover, while PCXII cells exhibited reduced NF-κB transcriptional activity, this was not restored by clusterin knock-down. These results indicate that Cox-2 induces clusterin in a 15d-PGJ(2)-dependent manner, and via activation of HSF-1 and PPARγ. However, the results do not support a model whereby Cox-2/15d-PGJ(2)-dependent inhibition of NF-κB signalling involves clusterin.


Subject(s)
Clusterin/metabolism , Prostaglandin D2/analogs & derivatives , Animals , Cyclooxygenase 2/metabolism , DNA-Binding Proteins/metabolism , Gene Knockdown Techniques , Heat Shock Transcription Factors , Intercellular Adhesion Molecule-1/metabolism , Isopropyl Thiogalactoside/pharmacology , NF-kappa B/metabolism , PC12 Cells , PPAR gamma/metabolism , Prostaglandin D2/metabolism , Rats , Signal Transduction/drug effects , Transcription Factors/metabolism , Transcription, Genetic/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effects
16.
Angiology ; 60(5): 576-81, 2009.
Article in English | MEDLINE | ID: mdl-19625268

ABSTRACT

INTRODUCTION: Cyclooxygenase (COX)-2 influences cardiovascular disease and serum concentration of high-sensitivity C-reactive protein (hsCRP). The study purpose was to determine the influence of single nucleotide polymorphisms (SNPs) of the COX-2 gene on abdominal aortic aneurysm (AAA) development and serum hsCRP concentrations. PATIENTS AND METHODS: Patients with AAA and disease-free controls were recruited. High-sensitivity C-reactive protein was measured by an enzyme-linked immunosorbent assay (ELISA) test. The distributions of COX-2 SNPs were investigated (rs20417 and rs4648307). The influence of the COX-2 SNPs on the hsCRP serum concentration was assessed. RESULTS: A total of 230 patients with AAA and 279 controls were included. No difference was found in the genotype distribution of the COX-2 SNPs rs20417 (P = .26) and rs4648307 (P = .90). They did not influence the hsCRP concentration (P = .24 and P = .61, respectively). Haplotype analysis of COX-2 SNPs revealed no difference. CONCLUSION: These COX-2 SNPs do not play any role in AAA development and do not influence serum hsCRP. These results differentiate AAA development from atherosclerotic diseases.


Subject(s)
Aortic Aneurysm, Abdominal/genetics , Cyclooxygenase 2/genetics , Inflammation/genetics , Polymorphism, Single Nucleotide , Aged , Aortic Aneurysm, Abdominal/blood , Aortic Aneurysm, Abdominal/enzymology , Biomarkers/blood , C-Reactive Protein/analysis , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Gene Frequency , Genetic Predisposition to Disease , Haplotypes , Humans , Inflammation/blood , Inflammation/enzymology , Linkage Disequilibrium , Male , Phenotype , Risk Factors
17.
Kidney Int ; 75(1): 31-40, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18784646

ABSTRACT

The guanine nucleotide exchange factor C3G, along with the CrkII adaptor protein, mediates GTP activation of the small GTPase proteins Rap1 and R-Ras, facilitating their activation of downstream signaling pathways, which had been found to be important in the pathogenesis of glomerulonephritis. We found that expression of C3G protein was upregulated in glomerular epithelial cells in an experimental model of accelerated anti-GBM antibody-induced glomerulonephritis expression. To determine the consequence of its increased expression, we transfected C3G (using adenoviral constructs) into cultured glomerular epithelial cells and measured the activated forms (i.e., GTP-bound) forms of Rap1 and R-Ras. Activation of Rap1 was not affected by C3G; however, the basal level of GTP-bound R-Ras was decreased. Further, C3G over-expression enhanced the activation of R-Ras in response to endothelin. Overexpression of C3G also led to a significant reduction in glomerular epithelial cell spreading and decreased the cells' E-cadherin expression and augmented their migration. We found that C3G was overexpressed in accelerated anti-GBM antibody-induced glomerulonephritis and suggest that this modulates glomerular epithelial cell morphology and behavior.


Subject(s)
Autoantibodies/adverse effects , Glomerulonephritis/metabolism , Guanine Nucleotide-Releasing Factor 2/genetics , Kidney Glomerulus/pathology , Animals , Cadherins/genetics , Cell Adhesion , Cell Movement , Epithelial Cells/metabolism , Epithelial Cells/pathology , Gene Expression , Glomerulonephritis/chemically induced , Kidney Glomerulus/metabolism , Male , Rats , Rats, Sprague-Dawley
18.
Neuroendocrinology ; 86(2): 104-11, 2007.
Article in English | MEDLINE | ID: mdl-17700013

ABSTRACT

BACKGROUND/AIMS: Mid-gut carcinoids (MGC) are the most common of the gastrointestinal carcinoid tumours. There is a lack of reliable prognostic indicators for MGC. Cox-2 and Bcl-2 were evaluated as prognostic biomarkers in a cohort of well-characterised non-appendiceal MGC. METHODS: Tissue from the primary MGC tumours of 37 patients was subjected to immunohistochemical detection of Cox-2 and Bcl-2. In 9 cases, tissue from secondary lesions was also examined. The study assessed whether tumour-associated Cox-2 and Bcl-2 expression were related to patient survival. RESULTS: Cox-2 expression was demonstrated in 30/36 primary tumours. When all tumours were analysed, Cox regression analysis indicated a trend towards worsening survival with increasing Cox-2 histoscore (intensity x proportion; hazard ratio 1.53, 95% CI 0.93, 2.52; p = 0.09). Analysis of Cox-2-positive tumours revealed a highly significant association between increasing histoscore and decreased survival (hazard ratio 3.03, 95% CI 1.33, 6.91; p = 0.008). Tumour-associated Bcl-2 expression had no effect on patient survival (hazard ratio 1.12, 95% CI 0.42, 2.99; p = 0.82). There was no significant association between Cox-2 and Bcl-2 expression (chi(2) p = 0.16), or Cox-2 histoscore and Bcl-2 expression (MWU p = 0.59). Analysis of the Cox-2 histoscores of primary tumours and their corresponding secondary lesions revealed a statistically significant trend towards increasing histoscore in the latter (Wilcoxon p = 0.04). CONCLUSIONS: This study has provided evidence that Cox-2 expression in primary MGC may be associated with a more negative prognostic outlook.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoid Tumor/metabolism , Carcinoid Tumor/pathology , Cyclooxygenase 2/metabolism , Intestinal Neoplasms/metabolism , Intestinal Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Appendix/pathology , Carcinoid Tumor/mortality , Colon/pathology , Female , Humans , Intestinal Neoplasms/mortality , Intestine, Small/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Male , Middle Aged , Prognosis , Proportional Hazards Models , Proto-Oncogene Proteins c-bcl-2/metabolism
19.
Endocrinology ; 148(9): 4310-7, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17540723

ABSTRACT

The prostanoid biosynthetic enzyme cyclooxygenase-2 (Cox-2) is up-regulated in several neuroendocrine tumors. The aim of the current study was to employ a neuroendocrine cell (PC12) model of Cox-2 overexpression to identify gene products that might be implicated in the oncogenic and/or inflammatory actions of this enzyme in the setting of neuroendocrine neoplasia. Expression array and real-time PCR analysis demonstrated that levels of the neuroendocrine marker chromogranin A (CGA) were 2- and 3.2-fold higher, respectively, in Cox-2 overexpressing cells (PCXII) vs. their control (PCMT) counterparts. Immunocytochemical and immunoblotting analyses confirmed that both intracellular and secreted levels of CGA were elevated in response to Cox-2 induction. Moreover, exogenous addition of prostaglandin E(2) (1 microm) mimicked this effect in PCMT cells, whereas treatment of PCXII cells with the Cox-2 selective inhibitor NS-398 (100 nm) reduced CGA expression levels, thereby confirming the biospecificity of this finding. Levels of neuron-specific enolase were similar in the two cell lines, suggesting that the effect of Cox-2 on CGA expression was specific and not due to a global enhancement of neuroendocrine marker expression/differentiation. Cox-2-dependent CGA up-regulation was associated with significantly increased chromaffin granule number and intracellular and secreted levels of dopamine. CGA promoter-driven reporter gene expression studies provided evidence that prostaglandin E(2)-dependent up-regulation required a proximal cAMP-responsive element (-71 to -64 bp). This study is the first to demonstrate that Cox-2 up-regulates both CGA expression and bioactivity in a neuroendocrine cell line and has major implications for the role of this polypeptide in the pathogenesis of neuroendocrine cancers in which Cox-2 is up-regulated.


Subject(s)
Chromogranin A/genetics , Chromogranin A/metabolism , Cyclooxygenase 2/genetics , Dinoprostone/pharmacology , Dinoprostone/physiology , Animals , Cyclic AMP , Gene Expression Regulation, Neoplastic/drug effects , Oligonucleotide Array Sequence Analysis , PC12 Cells , Polymerase Chain Reaction , RNA, Neoplasm/genetics , Rats , Transfection
20.
J Am Soc Nephrol ; 12(6): 1137-1150, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11373337

ABSTRACT

Endothelin-1 (ET-1) has been implicated in the pathogenesis of renal inflammation. This study investigated the mechanisms underlying the synergistic upregulation of preproET-1 gene expression in human mesangial cells after co-stimulation with thrombin and tumor necrosis factor alpha (TNFalpha). Whereas thrombin induced a moderate upregulation of preproET-1 mRNA, co-stimulation with TNFalpha resulted in a strong and protracted upregulation of this mRNA species. Thrombin+TNFalpha-induced upregulation of preproET-1 expression was found to require p38 mitogen-activated protein kinase and protein kinases C, whereas activation of extracellular signal-regulated kinase, c-Jun-N-terminal kinase, or intracellular Ca(2+) release were not required. Actinomycin D chase experiments suggested that enhanced stability of preproET-1 mRNA did not account for the increase in transcript levels. PreproET-1 promoter analysis demonstrated that the 5'-flanking region of preproET-1 encompassed positive regulatory elements engaged by thrombin. Negative modulation of thrombin-induced activation exerted by the distal 5' portion of preproET-1 promoter (-4.4 kbp to 204 bp) was overcome by co-stimulation with TNFalpha, providing a possible mechanism underlying the synergistic upregulation of preproET-1 expression by these two agonists. In conclusion, human mesangial cell expression of preproET-1 may be increased potently in the presence of two common proinflammatory mediators, thereby providing a potential mechanism for ET-1 production in inflammatory renal disease.


Subject(s)
Endothelins/genetics , Endothelium, Vascular/cytology , Gene Expression Regulation , Glomerular Mesangium/cytology , Mitogen-Activated Protein Kinases/metabolism , Protein Kinase C/metabolism , Protein-Tyrosine Kinases/metabolism , Animals , Blotting, Northern , Calcium/metabolism , Cells, Cultured , Chloramphenicol O-Acetyltransferase/pharmacology , Endothelins/analysis , Endothelins/metabolism , Endothelium, Vascular/metabolism , Female , Genetic Vectors , Humans , Male , Mitogen-Activated Protein Kinase 11 , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Thrombin/pharmacology , Transfection , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...